Business context and reporting period
The supplied filing is Oculus Innovative Sciences, Inc.’s Form 10-Q for the quarter ended December 31, 2014, not a Sonoma Pharmaceuticals filing. It covers the three- and nine-month periods ended December 31, 2014. Oculus develops and sells dermatology and advanced tissue-care products based on its Microcyn technology, along with licensing and testing services.
Financial performance and position
Unless stated otherwise, amounts are in millions of dollars.
| Metric | Quarter ended Dec. 31, 2014 | Nine months ended Dec. 31, 2014 | Prior comparable period |
|---|---|---|---|
| Revenue | $3.218 | $9.874 | $3.293 / $10.754 |
| Gross profit | $1.656 | $5.294 | $2.109 / $7.014 |
| Operating loss | $(1.949) | $(5.007) | $(1.546) / $(3.943) |
| Net loss | $(5.914) | $(6.702) | $(0.611) / $(3.722) |
| Basic and diluted loss per share | $(0.69) | $(0.79) | $(0.09) / $(0.56) |
| Operating cash used | Not provided for quarter | $(4.064) | $(3.401) |
- Revenue fell about 2% in the quarter and 8% for the nine-month period. Product and licensing revenue was weaker overall; U.S. sales declined, partly offset by growth in Mexico and Europe/rest of world.
- Product gross margin fell to 53% from 67% for the quarter and to 56% from 68% for the nine months, primarily reflecting lower U.S. sales of higher-margin products.
- Nine-month cash declined $3.240 to $2.240. At December 31, current assets were $5.197 and current liabilities $3.519, yielding working capital of $1.678. Total debt was approximately $0.006, all current; the company said prior Venture Lending debt had been settled in December 2013.
- Total assets were $11.834, including a $5.500 long-term investment in Ruthigen before the reported impairment adjustment. Accumulated deficit was $140.712.
Changes, outlook, and material items
- Quarterly net loss included a $4.650 impairment charge on the Ruthigen investment. A $0.679 noncash gain from a decrease in derivative liabilities partially offset losses; the nine-month gain was $2.998. These fair-value items materially affect comparisons.
- After quarter-end, the January 26, 2015 stock-and-warrant offering generated $6.259 gross and $5.300 net proceeds. It comprised 6.25 million common shares and warrants for 4.6875 million shares, plus warrants issued through a partial over-allotment exercise. The financing improves liquidity but creates substantial potential dilution.
- Management expects continued losses and said additional capital may be needed. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Without financing, it may reduce R&D or other costs, potentially delaying commercialization.
- Management expected R&D expense to decline near term as Ruthigen-related costs subsided, while SG&A was expected to rise as the direct sales force expanded. No specific revenue or earnings guidance was provided.
- Animal-health partner Innovacyn was transitioning to another supplier; Oculus terminated the arrangements in December. Related revenue was $0.122 for the quarter versus $0.652, and $1.110 for nine months versus $2.682. Replacement partners were under discussion, with no assurance of equivalent revenue.
- A significant customer, Exeltis (formerly Quinnova), alleged that Alevicyn gel sales breached an exclusive agreement and demanded that sales stop. Oculus disputed the claim, planned to defend it, and recorded no loss accrual.
- One customer accounted for 45% of revenue in both the quarter and nine-month period. More Pharma, a major Mexican counterparty, was acquired by Sanfer after quarter-end; the filing says the agreements transfer, but the impact and timing were uncertain.
- Common stock fell below $1 on January 21, 2015. The filing warns that continued noncompliance with Nasdaq’s minimum-bid requirement could lead to delisting and impair liquidity and access to capital.
- Management concluded disclosure controls were effective as of December 31, 2014; no material change in internal control over financial reporting was reported for the quarter.
Key facts for investors to verify
- Confirm the issuer identity: this source is an Oculus Innovative Sciences filing, despite the Sonoma Pharmaceuticals request metadata.
- Assess cash runway and going-concern risk, including the use of the $5.300 million net offering proceeds and any further financing needs.
- Track U.S. sales, product margins, animal-health replacement distribution, and customer concentration.
- Verify whether the Ruthigen sale trigger occurred; as of February 12, 2015, none had occurred, and completion was not assured.
- Monitor the Quinnova dispute, Nasdaq listing compliance, and potential dilution from outstanding and newly issued warrants.